Biogen Inc. stock underperforms Friday when compared to competitors
Biogen Inc. closed 41.60% below its 52-week high of $246.44, which the company achieved on February 7th.
Biogen Inc. (NASDAQ:BIIB) Shares Sold by Fifth Third Bancorp
Fifth Third Bancorp reduced its stake in Biogen Inc. (NASDAQ:BIIB – Free Report) by 3.4% in the fourth quarter, ...
FierceBiotech9d
Biogen research team hit by layoffs as company shifts resources to external opportunities
Biogen has been in the news recently after longtime partner Sage Therapeutics filed a lawsuit against the company after ...
Biogen (BIIB) Gets a Hold from Piper Sandler
In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...
Sage rejects Biogen’s buyout offer, but says it's open to deals
Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen ...
American Association of Individual Investors1d
Which Is a Better Investment, Biogen Inc. or Natera, Inc. Stock?
Learn more about whether Biogen Inc. or Natera, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Breaking Down Biogen: 18 Analysts Share Their Views
The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...
Biogen CEO tells Governor Healey he’s concerned about ‘a lot more policy risk’ in D.C.
Chris Viehbacher spoke out about the uncertain policy environment for life sciences companies, though he didn't single ...
BioSpace21h
You Can’t Buy Us: Biotechs Turn to Courts to Fight Off Potential Buyers
Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO ...